The findings of the present study imply that ALKBH5 is a potential biomarker to predict the response of patients with NSCLC to anti PD-L1 immunotherapy, and that targeting ALKBH5 may be a promising strategy to enhance anti-tumor immunity. This evidence concerns the gene ALKBH5 and neoplasm.